Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors

US11472791B2 · kind B2 · utility

Assignee

• Incyte Corporation · US

Inventors

• Joshua Hummel · Hockessin, US
• Jingwei Li · Beijing, CN
• Zhenwu Li · Wilmington, US
• Ding-Quan Qian · Newark, US
• Liangxing Wu · Wilmington, US
• Kaijiong Xiao · Clark, US
• Meizhong Xu · Hockessin, US
• Jeffrey Yang · Wilmington, US
• Wenqing Yao · Kennett Square, US
• Fenglei Zhang · Berwyn, US
• Min Ye · Ward, US
• Yingnan Chen · Wilmington, US
• Margaret Favata · North East, US
• Yvonne Lo · Hockessin, US

Key dates

• Filing date: Mar 4, 2020
• Grant date: Oct 18, 2022
• Expiry date: Mar 4, 2040

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N33/5011
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application provides pyrazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.